UBS AM’s Fennec Pharmaceuticals FENC Stock Holding History

UBS AM’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.26K	Hold	303	–	–	﹤0.01%	3466
2026 Q1	$1.86K	Hold	303	–	–	﹤0.01%	3609
2025 Q4	$2.33K	Buy	+303	New	+$2.49K	﹤0.01%	3107

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS AM's FENC Position: Q2 2026 in Review

UBS AM held its Fennec Pharmaceuticals (FENC) position steady in Q2 2026 at 303 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #3466.

UBS AM first reported a position in FENC in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

UBS AM held 303 shares of Fennec Pharmaceuticals worth $3.26K as of Q2 2026.
UBS AM left its Fennec Pharmaceuticals share count unchanged in Q2 2026.
Fennec Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3466 holding.
UBS AM first reported a position in Fennec Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.